RT Journal Article
SR Electronic
T1 What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5615
OP 5621
VO 35
IS 10
A1 DAVIES, RHIAN SIÂN
A1 SMITH, CHRISTIAN
A1 BUTTON, MICHAEL ROBERT
A1 TANGUAY, JACOB
A1 BARBER, JIM
A1 PALANIAPPAN, NACHIAPPAN
A1 STAFFURTH, JOHN
A1 LESTER, JASON FRANCIS
YR 2015
UL http://ar.iiarjournals.org/content/35/10/5615.abstract
AB Background: Several treatments have been shown to prolong survival in metastatic castrate-resistant prostate cancer (mCRPC); the optimum sequencing of these is not established. We investigated methods of identifying patients with mCRPC unlikely to respond to abiraterone. Patients and Methods: A retrospective analysis was carried-out in 47 consecutive patients with mCRPC treated sequentially with androgen deprivation (LHRHa), bicalutamide, docetaxel then abiraterone. Results: The median progression-free survival in patients treated with abiraterone was shorter in those with ≤18 months' response to LHRHa (118 vs. 279 days; p=0.018), bicalutamide non-responders (91 vs. 196 days; p=0.003) and patients with ≤6 months' response to docetaxel (102 vs. 294 days; p<0.001). The median overall survival was also shorter (348 vs. 815 days, p=0.016; 413 vs. 752 days, p=0.009; and 325 vs. 727 days, p<0.04, respectively). Conclusion: A response of ≤18 months' to LHRHa, non-response to bicalutamide and ≤6 months' response to docetaxel predicted poor response to abiraterone.